These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19418054)
1. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma? Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054 [TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680 [TBL] [Abstract][Full Text] [Related]
3. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572 [TBL] [Abstract][Full Text] [Related]
4. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients. Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182 [TBL] [Abstract][Full Text] [Related]
6. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112 [TBL] [Abstract][Full Text] [Related]
7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
8. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845 [TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
12. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. Batgi H; Merdin A; Dal MS; Kızıl Çakar M; Yıldız J; Başçı S; Uncu Ulu B; Yiğenoğlu TN; Darçın T; Şahin D; Bakırtaş M; Tetik A; İskender D; Altuntaş F J Oncol Pharm Pract; 2020 Dec; 26(8):1857-1863. PubMed ID: 32098553 [TBL] [Abstract][Full Text] [Related]
13. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Shafey M; Duan Q; Russell J; Duggan P; Balogh A; Stewart DA Leuk Lymphoma; 2012 Apr; 53(4):596-602. PubMed ID: 21929284 [TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Haq R; Sawka CA; Franssen E; Berinstein NL Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790 [TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518 [TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience. Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma. Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480 [TBL] [Abstract][Full Text] [Related]
19. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
20. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]